ResourceLife Sciences
Developing revolutionary new drugs from monoclonal antibodies that target GPCRs
4 Jun 2020Find out how Dr. Kiyoshi Takayama, President of NB Health Laboratory, is using the Intellicyt iQue3 to develop revolutionary new drugs from mAbs that target G-protein coupled receptors (GPCRs).
Related products
Request Quote for All Products
Links
Tags
AntibodiesAntibodies are used in techniques such as confocal and fluorescence microscopy, flow cytometry, ELISA, ELISPOT, immunohistochemistry, western blotting and immunopreciptation. Select specific antigen reactivity, high specific affinity, low non-specific binding, monoclonal or polyclonal, primary or secondary antibodies and associated conjugates such as an enzyme or dye for visualization.Monoclonal AntibodiesMonoclonal antibodies (mAbs) are lab-made molecules that can bind to specific antigens on cells, making them highly effective in treating cancers, autoimmune diseases, and infections. These targeted therapies are transforming the treatment landscape for many conditions. Browse our peer-reviewed product directory to find monoclonal antibodies for research and clinical applications; compare products, check reviews, and get pricing directly from manufacturers.Drug DevelopmentDrug development refers to the process of bringing a new drug to market.